New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.
<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) in...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:bb1a37dcdfb54bc8bfafdf5d75194975 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:bb1a37dcdfb54bc8bfafdf5d751949752021-11-18T08:21:37ZNew genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.1932-620310.1371/journal.pone.0095080https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d751949752014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24762746/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) inhibits TPMT activity, and that increased 6-thioguanine nucleotide (6-TGN, a metabolite of AZA) blood concentrations result in an increased number of ADRs. In this study, single nucleotide polymorphisms (SNPs) related to differential gene expression affecting AZA drug metabolism in combination therapy with 5-ASA were examined.<h4>Methods</h4>To identify genetic biomarkers for the prediction of 6-TGN blood concentration, ExpressGenotyping analysis was used. ExpressGenotyping analysis is able to detect critical pharmacogenetic SNPs by analyzing drug-induced expression allelic imbalance (EAI) of premature RNA in HapMap lymphocytes. We collected blood samples on 38 patients with inflammatory bowel disease treated with AZA and corroboration of the obtained SNPs was attempted in clinical samples.<h4>Results</h4>A large number of SNPs with AZA/5-ASA-induced EAI within the investigated HapMap lymphocytes was identified by ExpressGenotyping analysis. The respective SNPs were analyzed in IBD patients' blood samples. Among these SNPs, several that have not yet been described to be induced by AZA/5-ASA were found. SNPs within SLC38A9 showed a particular correlation with patients' 6-TGN blood concentrations.<h4>Conclusions</h4>Based on these results, ExpressGenotyping analysis and genotyping of patients appears to be a useful way to identify inter-individual differences in drug responses and ADRs to AZA/5-ASA. This study provides helpful information on genetic biomarkers for optimized AZA/5-ASA treatment of IBD patients.Kazuhiko UchiyamaTomohisa TakagiYasunori IwamotoNorihiko KondoTetsuya OkayamaNaohisa YoshidaKazuhiro KamadaKazuhiro KatadaOsamu HandaTakeshi IshikawaHiroaki YasudaJunichi SakagamiHideyuki KonishiNobuaki YagiYuji NaitoYoshito ItohPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 4, p e95080 (2014) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Kazuhiko Uchiyama Tomohisa Takagi Yasunori Iwamoto Norihiko Kondo Tetsuya Okayama Naohisa Yoshida Kazuhiro Kamada Kazuhiro Katada Osamu Handa Takeshi Ishikawa Hiroaki Yasuda Junichi Sakagami Hideyuki Konishi Nobuaki Yagi Yuji Naito Yoshito Itoh New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
description |
<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) inhibits TPMT activity, and that increased 6-thioguanine nucleotide (6-TGN, a metabolite of AZA) blood concentrations result in an increased number of ADRs. In this study, single nucleotide polymorphisms (SNPs) related to differential gene expression affecting AZA drug metabolism in combination therapy with 5-ASA were examined.<h4>Methods</h4>To identify genetic biomarkers for the prediction of 6-TGN blood concentration, ExpressGenotyping analysis was used. ExpressGenotyping analysis is able to detect critical pharmacogenetic SNPs by analyzing drug-induced expression allelic imbalance (EAI) of premature RNA in HapMap lymphocytes. We collected blood samples on 38 patients with inflammatory bowel disease treated with AZA and corroboration of the obtained SNPs was attempted in clinical samples.<h4>Results</h4>A large number of SNPs with AZA/5-ASA-induced EAI within the investigated HapMap lymphocytes was identified by ExpressGenotyping analysis. The respective SNPs were analyzed in IBD patients' blood samples. Among these SNPs, several that have not yet been described to be induced by AZA/5-ASA were found. SNPs within SLC38A9 showed a particular correlation with patients' 6-TGN blood concentrations.<h4>Conclusions</h4>Based on these results, ExpressGenotyping analysis and genotyping of patients appears to be a useful way to identify inter-individual differences in drug responses and ADRs to AZA/5-ASA. This study provides helpful information on genetic biomarkers for optimized AZA/5-ASA treatment of IBD patients. |
format |
article |
author |
Kazuhiko Uchiyama Tomohisa Takagi Yasunori Iwamoto Norihiko Kondo Tetsuya Okayama Naohisa Yoshida Kazuhiro Kamada Kazuhiro Katada Osamu Handa Takeshi Ishikawa Hiroaki Yasuda Junichi Sakagami Hideyuki Konishi Nobuaki Yagi Yuji Naito Yoshito Itoh |
author_facet |
Kazuhiko Uchiyama Tomohisa Takagi Yasunori Iwamoto Norihiko Kondo Tetsuya Okayama Naohisa Yoshida Kazuhiro Kamada Kazuhiro Katada Osamu Handa Takeshi Ishikawa Hiroaki Yasuda Junichi Sakagami Hideyuki Konishi Nobuaki Yagi Yuji Naito Yoshito Itoh |
author_sort |
Kazuhiko Uchiyama |
title |
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
title_short |
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
title_full |
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
title_fullStr |
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
title_full_unstemmed |
New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
title_sort |
new genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid. |
publisher |
Public Library of Science (PLoS) |
publishDate |
2014 |
url |
https://doaj.org/article/bb1a37dcdfb54bc8bfafdf5d75194975 |
work_keys_str_mv |
AT kazuhikouchiyama newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT tomohisatakagi newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT yasunoriiwamoto newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT norihikokondo newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT tetsuyaokayama newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT naohisayoshida newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT kazuhirokamada newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT kazuhirokatada newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT osamuhanda newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT takeshiishikawa newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT hiroakiyasuda newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT junichisakagami newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT hideyukikonishi newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT nobuakiyagi newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT yujinaito newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid AT yoshitoitoh newgeneticbiomarkerspredictingazathioprinebloodconcentrationsincombinationtherapywith5aminosalicylicacid |
_version_ |
1718421884991700992 |